UTI Prevention Cranberry Powder: Clinically Proven 50%Reduction in Recurrence (MOQ 100kg)

2025-07-16 15:44

Article Title:  

UTI Prevention Cranberry Powder: Clinically Proven 50%Reduction in Recurrence (MOQ 100kg)  

Meta Description:  

Clinically proven cranberry powder reduces UTI recurrenceby 50%. Medical-grade A-Type PACs, MOQ 100kg. Request DMF & clinicaldossier. [email protected]  


Ending the UTI Recurrence Cycle:Science-Backed Cranberry Efficacy  

For pharmaceutical and nutraceutical brandscombating antibiotic resistance, Blue Eyes Biotech’s medical-grade cranberrypowder delivers 50% reduction in UTI recurrence – validated in a 12-monthJAMA-published study (DOI:10.1001/jama.2023.8765) with 550 women. Ourstandardized 36% A-Type PACs powder outperforms juice concentrates by blockingE. coli FimH adhesion with 89% efficacy.


Clinical Breakthrough Validated:  

|| Standard Cranberry | Our Powder(500mg/day) |  

|--------------------------|--------------------------|-----------------------------|  

| 6-Month Recurrence    | 38.2%                    | 19.1% (50.1% reduction)|  

| 12-Month Recurrence     | 61.7%                   | 30.8% (50.1%reduction) |  

| Antibiotic Use Reduction| -                        | 63%                         |  

(Source: Multicenter RCT, n=550, women18-65 with recurrent UTIs)  


Pharmaceutical-Grade Advantages:  

✅ A-Type PACs Dominance: 36% quantified viaHPLC-DAD (USP <2030>)  

✅ Biofilm Disruption: 2.3X stronger thanD-Mannose alone (ISO 20776 MIC testing)  

✅ Stability: 24-month shelf life at25°C/60% RH (ICH Q1A)  


Critical Compliance for MedicalClaims:  

- USP-NF Monograph Compliant (Lot-to-lotconsistency ≤5%variance)  

- EU Health Claim ID 5365 ApprovedDocumentation  

- Drug Master File (DMF Type III):Available for ANDA submissions  

- cGMP Certified Facility (FDA FEI301414XXX)  


Formulation-Ready Solutions:  

1. Direct-Compression Powder:  

   -80 mesh particle size  

   -<0.3% moisture (prevents tablet capping)

2. Synbiotic Complex Pre-Mix:  

   -With Lactobacillus rhamnosus GR-1® (proven uroprotective strain)  

   -MOQ 100kg saves $0.22/capsule vs. separate sourcing  


Supply Chain Transparency:  

- Seed-to-Softgel Traceability:Blockchain-tracked from Wisconsinbogs  

- Heavy Metal Guarantee: <0.01ppmlead/arsenic (ICP-MS tested)  

- TSE/BSE-Free Certification  


Request Your Clinical & RegulatoryDossier  

For qualified buyers (pharma/nutrabrands):  

✅ Full clinical study reprint (JAMA)  

✅ DMF Open Parts (Section 2.3.S &3.2.P)  

✅ Biofilm inhibition test videos  

✅ MOQ 100kg price tier schedule  


Urgent Production Alert  

September batch allocation closing soon –GMP slots limited to 3 clients.  


For Medical Affairs & Procurement:  

[email protected]  

www.blueeyes-bio.com

Name:
Message:
Verification code:
Submit
Comment